|1.||Guo, Ju-Tao: 1 article (01/2015)|
|2.||Chang, Jinhong: 1 article (01/2015)|
|3.||Block, Timothy M: 1 article (01/2015)|
|4.||Takase, Juri: 1 article (10/2013)|
|5.||Amamoto, Ryuta: 1 article (10/2013)|
|6.||Ashida, Hisashi: 1 article (10/2013)|
|7.||Katoh, Toshihiko: 1 article (10/2013)|
|8.||Aoshima, Naofumi: 1 article (10/2013)|
|9.||Tiemeyer, Michael: 1 article (10/2013)|
|10.||Yamamoto, Kenji: 1 article (10/2013)|
|1.||Congenital, Hereditary, and Neonatal Diseases and Abnormalities (Congenital Disorders)
11/26/2004 - "The Lec23 Chinese hamster ovary mutant is a sensitive host for detecting mutations in alpha-glucosidase I that give rise to congenital disorder of glycosylation IIb (CDG IIb)."
10/01/2013 - "This reaction is critical to the subsequent processing of N-glycans and thus defects in α-glucosidase I gene in human cause congenital disorder of glycosylation (CDG) type IIb. "
08/01/2002 - "Recently, we reported a novel congenital disorder of glycosylation (CDG-IIb) caused by severe deficiency of the glucosidase I. The enzyme cleaves the alpha1,2-glucose residue from the asparagine-linked Glc(3)-Man(9)-GlcNAc(2) precursor, which is crucial for oligosaccharide maturation. "
08/01/2009 - "Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection."
07/01/2012 - "Recently, Celgosivir (MIGENIX Inc) is an oral prodrug of the natural product castanospermine used for the treatment of HCV infection by inhibiting α-glucosidase I. BMN-701 is an α-glucosidase inhibitors in the phase I pipeline (BioMarine) for the treatment of Pompe diseases. "
08/01/2009 - "Celgosivir, in development by MIGENIX Inc for the treatment of HCV infection, is an oral prodrug of the natural product castanospermine that inhibits alpha-glucosidase I, an enzyme that plays a critical role in viral maturation by initiating the processing of the N-linked oligosaccharides of viral envelope glycoproteins. "
04/01/1989 - "We have found that fresh human serum enhances the infectivity of HIV-1 in MT-2 cell infection assays when virus is synthesized in the presence of the mannosidase I inhibitor, 1-deoxymannojirimycin, or the mannosidase II inhibitor, swainsonine, but has no enhancing effect on virus synthesized in the presence of the glucosidase I inhibitors, castanospermine and 1-deoxynojirimycin, or the glucosidase II inhibitor, bromoconduritol. "
|3.||Hepatocellular Carcinoma (Hepatoma)
12/15/1985 - "Thus the alkaloid inhibits glucosidase I in the human hepatoma cells. "
12/15/1985 - "Castanospermine inhibits glucosidase I and glycoprotein secretion in human hepatoma cells."
11/01/1986 - "To investigate our earlier hypothesis that carbohydrates play a regulatory role in the intracellular transport of secretory glycoproteins, we used 1-deoxynojirimycin (DNJ), and inhibitor of glucosidase I and II of the rough endoplasmic reticulum (RER), to modify the structure of N-linked glycan moieties of secretory glycoproteins of human hepatoma (Hep G2) cells in culture. "
07/18/1994 - "We studied the effect of the glucosidase I inhibitor, N-methyl-1-deoxynojirimycin (MdN) and the mannosidase inhibitor, 1-deoxymannojirimycin (dMM) on the biosynthesis and secretion of alpha 2-plasmin inhibitor (alpha 2-PI) and antithrombin III (ATIII) in cultures of human hepatoma (Hep-G2) cells. "
|4.||Congenital Disorders of Glycosylation
|3.||1-Deoxynojirimycin (1 Deoxynojirimycin)